APA

Mönch D., Bode-Erdmann S., Kalla J., Sträter J., Schwänen C., Falkenstern-Ge R., Klumpp S., Friedel G., Ott G. & Kalla C. (2018). A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy. : Oncotarget.

Chicago

Mönch Dina, Bode-Erdmann Sabine, Kalla Jörg, Sträter Jörn, Schwänen Carsten, Falkenstern-Ge Roger, Klumpp Siegfried, Friedel Godehard, Ott German and Kalla Claudia. 2018. A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy. : Oncotarget.

Harvard

Mönch D., Bode-Erdmann S., Kalla J., Sträter J., Schwänen C., Falkenstern-Ge R., Klumpp S., Friedel G., Ott G. and Kalla C. (2018). A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy. : Oncotarget.

MLA

Mönch Dina, Bode-Erdmann Sabine, Kalla Jörg, Sträter Jörn, Schwänen Carsten, Falkenstern-Ge Roger, Klumpp Siegfried, Friedel Godehard, Ott German and Kalla Claudia. A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy. : Oncotarget. 2018.